The global melanoma therapeutics market size was valued at USD 4.2 billion in 2016 and is anticipated to witness CAGR of 11.21% during the forecast period. Rising incidence of melanoma and other skin cancers is expected to accelerate demand for anticancer agents.
According to WHO, about 132,000 cases of skin cancer occur every year. Moreover, a 10% decrease in ozone levels is anticipated to lead to an increase of 4,500 skin cancer cases worldwide. This is anticipated to fuel demand for these drugs during the forecast period.
U.S. melanoma therapeutics market revenue by therapy, 2014 - 2025 (USD million)
Entry of biosimilars in the market is expected to increase during the forecast period due to patent expiration of key branded biologics. For instance, Amgen’s patent for Imlygic expires in 2021, and this is expected to offer opportunities for new players to enter the market, and, in turn, boost market growth.
Prevalence of skin allergies, melanoma, and other skin cancers in developing countries is high, which serves as an opportunity for drug companies to gain a larger share in these regions. Increasing demand for cost-efficient therapeutics in developing regions, such as Asia Pacific and Middle East & Africa, has encouraged major players to develop cheaper and effective drugs. These factors are expected to fuel growth of the overall market in coming years.
In 2016, chemotherapy captured around 7% of the therapy segment in terms of revenue. This can be attributed to its high adoption rate in the past few years due to increasing incidence of cancer, especially skin cancers. Chemotherapy includes a broad range of therapeutics that involve proteins and other synthetically derived products.
Immunotherapy held the largest share of the therapy segment. This can be attributed to effectiveness of drugs used in immunotherapy and an increase in their approvals. Strong emerging pipeline for melanoma treatment is expected to drive the immunotherapy segment over the forecast period.
Targeted therapy is anticipated to grow at a lucrative CAGR of about 18% owing to benefits such as limited adverse effects and higher efficiancy of targeted therapy drugs. Advancements in genomics have led to development of targeted cancer therapies for treatment of patients who are incurable by intensive cytotoxic chemotherapy.
Radiation therapy segment is expected to exhibit steady growth over the forecast period owing to increasing number of advanced melanoma cases and use of radiation as an adjuvant therapy post-surgery. Radiation therapy is rarely used as primary treatment. It is only administered to patients in stage 4, who cannot be treated with surgery.
Branded drugs segment held the largest revenue share in 2016 due to patent exclusivity. Presence of a large patient base and higher consumption of biologics are contributing toward its dominance. Moreover, availability of fewer generics as well as increased adoption of branded drugs in the treatment of melanoma has boosted growth of the branded drugs segment.
Branded drugs are expected to lose their market share over the forecast period due to patent expiration of notable brands such as Yervoy and Imlygic. Imlygic is expected to lose its patent protection in 2021, which will result in reduced revenue for Amgen, Inc. Similarly, Yervoy is expected to lose its patent exclusivity in the U.S. in 2022 and in Europe in 2020.
Generics are anticipated to gain momentum over the forecast period for treatment of melanoma. Generics are cost-effective, easy to develop, and receive approval in lesser time as compared to biologics, and this is expected to fuel growth of this segment over the forecast period.
There is a strong emerging pipeline of melanoma drugs. Many of these drugs are under clinical trials. For instance, the products of companies such as Celgene Corporation; Eisai Co., Ltd.; Moleculin Biotech, LLC; and Prima BioMed Ltd. are under phase 2 of clinical trials. Similarly, there are several companies focused on developing new therapeutics. These factors are expected to fuel market growth.
North America held a dominant share of the market as of 2016 owing to rising incidence of melanoma and other skin cancers in the region. According to CDC, over 71,943 people were affected by melanoma in 2013. As per American Cancer Society, this number is expected to go up to 87,100 cases in 2017. These statistics highlight the need for drugs that help in management of melanoma over the coming years.
The U.S. government has developed favorable reimbursement policies for treatment of these diseases in an attempt to fulfil unmet patient needs. This is expected to provide a healthy platform for growth to the North American market. Furthermore, owing to patent expiration of biologics in coming years, numerous new players are expected to enter the market in this region. The existing players are undertaking various strategic initiatives to improve their revenue share. For instance, in July 2016, Bristol-Myers Squibb Company acquired Cormorant Pharmaceuticals to broaden its immuno-oncology pipeline.
Global melanoma therapeutics market revenue, by region, 2016 (%)
The Asia Pacific market is expected to grow at a lucrative rate owing to constant rise in the incidence of skin cancer coupled with increased demand for cost-efficient therapeutics. Owing to presence of large number of clinical research organizations, several pharmaceutical firms are drawn to this region for production of effective and cheaper drugs.
Furthermore, increase in government initiatives for improving health care facilities in this region is another factor contributing to market growth. For instance, the Government of India approved establishment of State Cancer Institutes and Tertiary Care Cancer Centers in the country in 2013, which is expected to boost the regional market to a certain extent.
Some of the major players in this market are AstraZeneca; Amgen, Inc.; F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb Company; Novartis AG; Merck & Co., Inc.; Daiichi Sankyo Company, Limited; and AB Sciences.
The market is witnessing substantial growth owing to development and approval of new biologics as well as their growing demand, which has drawn several local and international companies to invest in developing these therapeutics.
The market is highly competitive in nature, with leading players involved in regional expansion, partnerships, new product development, and R&D to increase market penetration. Several products are under clinical trials in the U.S. & Europe, which are expected to receive approval during the forecast period. With an increasing number distributors and dealers for these drugs, the market is likely to continue witnessing high competitive rivalry over the forecast period.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million and CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, UK, Germany, Japan, China, India, Brazil, Mexico, South Africa
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
Segments covered in the report
This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global melanoma therapeutics market on the basis of therapy, drugs, and region:
Therapy Outlook (Revenue, USD Million, 2014 - 2025)
Drugs Outlook (Revenue, USD Million, 2014 - 2025)
Regional Outlook (Revenue, USD Million, 2014 - 2025)
The Middle East and Africa
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.